Dr Andrew Jk Smith Iii, MD | |
3800 Park Nicollet Blvd, Credentialing Dept, St Louis Park, MN 55416-2527 | |
(952) 993-6450 | |
Not Available |
Full Name | Dr Andrew Jk Smith Iii |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 27 Years |
Location | 3800 Park Nicollet Blvd, St Louis Park, Minnesota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699725101 | NPI | - | NPPES |
019391 | Other | CO | KAISER COMMERCIAL NUMBER |
72735759 | Medicaid | CO |
Facility Name | Location | Facility Type |
---|---|---|
Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
Hutchinson Health | Hutchinson, MN | Hospital |
Olivia Hospital & Clinic | Olivia, MN | Hospital |
St Francis Regional Medical Center | Shakopee, MN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Hutchinson Health | 0345330072 | 122 |
Park Nicollet Clinic | 7911819438 | 1529 |
News Archive
A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S. In 2009, the most recent year for which actual data are available, 29,935 people of Hispanic origin in the U.S. died of cancer, compared to 29,611 deaths from heart disease.
Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
...a hereditary, disfiguring bone disorder that can cause blindness and deafness. The findings provide insight into long-range gene regulation and could lead to new treatments for osteoporosis and other crippling bone disorders.
› Verified 9 days ago
Entity Name | Park Nicollet Clinic |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780621904 PECOS PAC ID: 7911819438 Enrollment ID: O20031104000046 |
News Archive
A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S. In 2009, the most recent year for which actual data are available, 29,935 people of Hispanic origin in the U.S. died of cancer, compared to 29,611 deaths from heart disease.
Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
...a hereditary, disfiguring bone disorder that can cause blindness and deafness. The findings provide insight into long-range gene regulation and could lead to new treatments for osteoporosis and other crippling bone disorders.
› Verified 9 days ago
Entity Name | Hutchinson Health |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1053508820 PECOS PAC ID: 0345330072 Enrollment ID: O20080312000695 |
News Archive
A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S. In 2009, the most recent year for which actual data are available, 29,935 people of Hispanic origin in the U.S. died of cancer, compared to 29,611 deaths from heart disease.
Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
...a hereditary, disfiguring bone disorder that can cause blindness and deafness. The findings provide insight into long-range gene regulation and could lead to new treatments for osteoporosis and other crippling bone disorders.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Andrew Jk Smith Iii, MD 3800 Park Nicollet Blvd, Credentialing Dept, St Louis Park, MN 55416-2527 Ph: (952) 993-6450 | Dr Andrew Jk Smith Iii, MD 3800 Park Nicollet Blvd, Credentialing Dept, St Louis Park, MN 55416-2527 Ph: (952) 993-6450 |
News Archive
A new report from American Cancer Society researchers finds that despite declining death rates, cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S. In 2009, the most recent year for which actual data are available, 29,935 people of Hispanic origin in the U.S. died of cancer, compared to 29,611 deaths from heart disease.
Levels of carbonic anhydrase 9 increase with the use of vascular endothelial growth factor-targeted therapy for metastatic clear-cell renal cancer, and high expression of this protein is associated with increased survival, show study results reported in European Urology.
Allos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Company's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
...a hereditary, disfiguring bone disorder that can cause blindness and deafness. The findings provide insight into long-range gene regulation and could lead to new treatments for osteoporosis and other crippling bone disorders.
› Verified 9 days ago
Cara Houle, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-5000 | |
Janet Grayson, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-6600 | |
Keith Harmon, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6490 Excelsior Blvd, Suite W300, St Louis Park, MN 55426 Phone: 952-993-3242 | |
Jeffrey J Shultz, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, Park Nicollet Clinic - Heart & Vascular Center, St Louis Park, MN 55426 Phone: 952-993-3246 Fax: 952-993-3010 | |
Amanda J Calvin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3931 Louisiana Ave S, St Louis Park, MN 55426 Phone: 952-993-3230 | |
Sarah Evert, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3850 Park Nicollet Blvd, St Louis Park, MN 55416 Phone: 952-993-3025 | |
Stevie Maxwell, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6500 Excelsior Blvd, St Louis Park, MN 55426 Phone: 952-993-5000 |